Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,378Revenue (TTM) $M15.0Net Margin (%)-838.3Altman Z-Score41.7
Enterprise Value $M3,025EPS (TTM) $-1.5Operating Margin %-879.1Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.8Pre-tax Margin (%)-838.3Higher ROA y-yY
Price/Book9.610-y EBITDA Growth Rate %--Quick Ratio13.4Cash flow > EarningsY
Price/Sales2255-y EBITDA Growth Rate %--Current Ratio13.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-27.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-31.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M86.9ROIC % (ttm)-474.2Gross Margin Increase y-yN

Gurus Latest Trades with NBIX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NBIXGeorge Soros 2016-09-30 Buy 0.02%$45.29 - $54.63
($49.8)
$ 38.84-22%New holding11,322
NBIXGeorge Soros 2016-06-30 Sold Out -0.01%$39.55 - $51.97
($45.94)
$ 38.84-15%Sold Out0
NBIXGeorge Soros 2016-03-31 Buy 0.01%$32.19 - $56.57
($40.01)
$ 38.84-3%New holding9,400
NBIXGeorge Soros 2013-09-30 Sold Out -0.03%$10.6 - $16.7
($13.79)
$ 38.84182%Sold Out0
NBIXGeorge Soros 2013-06-30 Buy 0.03%$10.9 - $13.57
($12.28)
$ 38.84216%New holding200,000
NBIXJoel Greenblatt 2012-12-31 Sold Out -0.13%$6.88 - $8.66
($7.6)
$ 38.84411%Sold Out0
NBIXJoel Greenblatt 2012-06-30 Add0.03%$6.31 - $8.06
($7.18)
$ 38.84441%Add 23.80%259,903
NBIXGeorge Soros 2012-06-30 Sold Out -0.02%$6.31 - $8.06
($7.18)
$ 38.84441%Sold Out0
NBIXJoel Greenblatt 2012-03-31 Buy 0.15%$7.33 - $9.79
($7.95)
$ 38.84389%New holding209,930
NBIXGeorge Soros 2012-03-31 Buy 0.02%$7.33 - $9.79
($7.95)
$ 38.84389%New holding150,000
NBIXGeorge Soros 2011-12-31 Sold Out -0.0018%$5.5 - $8.58
($6.76)
$ 38.84475%Sold Out0
NBIXGeorge Soros 2011-09-30 Reduce$5.59 - $8.44
($6.71)
$ 38.84479%Reduce -23.93%17,800
NBIXGeorge Soros 2011-06-30 Add$6.82 - $8.3
($7.54)
$ 38.84415%Add 90.24%23,400
NBIXGeorge Soros 2011-03-31 Add$6.47 - $7.84
($7.2)
$ 38.84439%Add 23.00%12,300
NBIXGeorge Soros 2010-12-31 Buy $5.99 - $8.53
($7.63)
$ 38.84409%New holding10,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NBIX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NBIX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Bozigian Haig P.Chief Development Officer 2017-01-17Sell1,625$40.63-4.41view
Coughlin Timothy PCFO 2017-01-17Sell1,750$40.65-4.45view
Gano KyleChief Business Development Off 2017-01-17Sell1,625$40.65-4.45view
GORMAN KEVIN CHARLESCEO 2017-01-17Sell3,750$40.65-4.45view
Grigoriadis Dimitri E.Chief Research Officer 2017-01-17Sell1,625$40.63-4.41view
OBrien Christopher FlintChief Medical Officer 2017-01-17Sell1,750$40.66-4.48view
Grigoriadis Dimitri E.Chief Research Officer 2017-01-10Sell1,625$43.39-10.49view
GORMAN KEVIN CHARLESCEO 2017-01-10Sell3,750$43.28-10.26view
Gano KyleChief Business Development Off 2017-01-10Sell1,250$43.37-10.45view
Coughlin Timothy PCFO 2017-01-10Sell1,750$43.37-10.45view

Quarterly/Annual Reports about NBIX:

News about NBIX:

Articles On GuruFocus.com
AbbVie: Encouraging Results From Elagolix Study Oct 20 2016 
Meridian Funds Comments on Neurocrine Biosciences Aug 31 2015 
Meridian Contrarian Fund Annual Report 2015 Aug 31 2015 
Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 

More From Other Websites
NBIX: Phase 2 Study of INGREZZA™ in Adults with Tourette Syndrome Fails to Hit Primary Endpoint Jan 19 2017
After hours buzz: CSX, UAL, GIMO & more Jan 17 2017
Neurocrine Med Failure, Jazz Pharma Generic Rival OK Sends Both Down Jan 17 2017
Neurocrine Drug Fails to Reduce Tic Severity in Tourette Syndrome Patients Jan 17 2017
Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™... Jan 17 2017
Here Are Two Market Moving Biotech Catalysts To Watch This Week Jan 17 2017
Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : January 11, 2017 Jan 11 2017
Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US :... Jan 10 2017
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 06 2017
NBIX: AdComm Meeting for INGREZZA™ Cancelled by FDA Jan 06 2017
What Does The Panel Cancellation Mean For Neurocrine Biosciences, Inc. (NBIX)? Jan 06 2017
These 5 Biotech Stocks Could Be Big Takeover Targets in 2017 Jan 06 2017
Neurocrine Biosciences Announces the Appointment of David-Alexandre Gros M.D. President and Chief... Jan 06 2017
Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment... Jan 05 2017
Neurocrine Provides Update on FDA Advisory Committee for INGREZZA™ (valbenazine) for the Treatment... Jan 05 2017
Neurocrine Biosciences to Present at the 35th Annual J.P. Morgan Healthcare Conference Jan 03 2017
7 Key FDA Decisions and Catalysts Expected in January and February Dec 30 2016
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers Dec 23 2016
Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down Dec 21 2016
Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down Dec 21 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)